Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bristol Myers Squibb (BMY)

Bristol Myers Squibb Q4 revenue rises 1% to $12.5 billion; non-GAAP EPS falls 25%

Mixed Impact 3 of 5 earnings Written later

Bristol Myers Squibb reported fourth-quarter 2025 revenue of $12.5 billion, up 1%, and non-GAAP earnings of $1.26 per share, down from $1.67 a year earlier. For full-year 2025, revenue was $48.2 billion, roughly flat, and non-GAAP EPS was $6.15, up from $1.15. The company guided 2026 revenue to $46.0 billion to $47.5 billion and non-GAAP EPS to $6.05 to $6.35.

Key points

  • Q4 revenue $12.5 billion, up 1%; Growth Portfolio $7.4 billion, up 16%; Legacy Portfolio $5.1 billion, down 15%
  • Q4 GAAP EPS $0.53 versus $0.04; non-GAAP EPS $1.26 versus $1.67, both including a $(0.60) net impact from Acquired IPRD charges and licensing income
  • Full-year 2025 revenue $48.2 billion versus $48.3 billion; GAAP EPS $3.46 versus $(4.41)
  • 2026 guidance: revenue $46.0 billion to $47.5 billion, non-GAAP EPS $6.05 to $6.35; quarterly dividend $0.63 per share, a 17th consecutive annual increase

The filing

CompanyBristol Myers Squibb (BMY)
Form8-K, current report
Filed with the SECFeb 5, 2026, 7:07 AM ET
Accession number0000014272-26-000002

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.